PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,080)

Items 201–300 of 1,080

1. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
   Coelho, Matthew A., de Carné Trécesson, Sophie, Rana, Sareena, Zecchin, Davide, Moore, Christopher, Molina-Arcas, Miriam, East, Philip, Spencer-Dene, Bradley, Nye, Emma, Barnouin, Karin et al. · 2017 · Immunity
2. DNA Damage and Repair Biomarkers of Immunotherapy Response
   Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
3. A molecular portrait of microsatellite instability across multiple cancers
   Isidro Cortés‐Ciriano, Sejoon Lee, Woong‐Yang Park, Tae‐Min Kim, Peter J. Park · 2017 · Nature Communications
4. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
   Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
5. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
   Charlene Marie Fares, Eliezer M. Van Allen, Charles G. Drake, James Patrick Allison, Siwen Hu‐Lieskovan · 2019 · American Society of Clinical Oncology Educational Book
6. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
   Eric W. Jonasch, Cheryl Lyn Walker, W. Kimryn Rathmell · 2020 · Nature Reviews Nephrology
7. Multiple primary tumours: challenges and approaches, a review
   Alexia Vogt, Sabine Schmid, Karl Heinimann, Harald Frick, C. Herrmann, Thomas Cerny, Aurelius Gabriel Omlin · 2017 · ESMO Open
8. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
   Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Alberto Bossi, Robert Glen Bristow, Brett Stewart Carver, Daniel Castellano, Byung Ha Chung, Noel William Clarke et al. · 2017 · European Urology
9. ESMO-magnitude of clinical benefit scale version 1.1
   Cherny, N.I., Dafni, U., Bogaerts, J., Latino, N.J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M.J., de Vries, E.G.E. · 2017 · Annals of Oncology
10. Cancer immunotherapies targeting the PD-1 signaling pathway
    Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Biomedical Science
11. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    Ignacio Melero, David M. Berman, Maria Angela Aznar, Alan J. Korman, José Luis Perez‐Gracia, John B.A.G. Haanen · 2015 · Nature reviews. Cancer
12. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
    Yelena Yuriy Janjigian, Johanna C. Bendell, Emiliano Calvo, Joseph W. Kim, Paolo A. Ascierto, Padmanee Sharma, Patrick Alexander Ott, Katriina Johanna Peltola, Dirk Jaeger, Jeffry Evans et al. · 2018 · Journal of Clinical Oncology
13. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
    Giovanni Germano, Simona Lamba, Giuseppe Rospo, Ludovic Barault, Alessandro Magrì, Federica Maione, Mariangela Russo, Giovanni Crisafulli, Alice Bartolini, Giulia Lerda et al. · 2017 · Nature
14. The emerging clinical relevance of genomics in cancer medicine
    Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
15. New Horizons for Precision Medicine in Biliary Tract Cancers
    Juan W. Valle, Ángela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew Xiuxuan Zhu · 2017 · Cancer Discovery
16. Classification of triple-negative breast cancers based on Immunogenomic profiling
    Yin He, Zehang Jiang, Cai Chen, Xiaosheng Wang · 2018 · Journal of Experimental & Clinical Cancer Research
17. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
    Jessica S. Brown, Brent O’Carrigan, Stephen P. Jackson, Timothy Anthony Yap · 2016 · Cancer Discovery
18. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
    Kyle C. Strickland, Brooke E. Howitt, Sachet Ashok Shukla, Scott J. Rodig, Lauren L. Ritterhouse, Joyce F. Liu, Judy Ellen Garber, Dipanjan Chowdhury, Catherine J. Wu, Alan D. D’Andrea et al. · 2016 · Oncotarget
19. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
    Miao, Diana, Margolis, Claire A., Vokes, Natalie I., Liu, David, Taylor-Weiner, Amaro, Wankowicz, Stephanie M., Adeegbe, Dennis, Keliher, Daniel, Schilling, Bastian, Tracy, Adam et al. · 2018 · Nature Genetics
20. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
    Alicia J. Latham, Preethi Srinivasan, Yelena M. Kemel, Jinru Shia, Chaitanya Bandlamudi, Diana L. Mandelker, Sumit Middha, Jaclyn Frances Hechtman, Ahmet Zehir, Marianne E. Dubard-Gault et al. · 2018 · Journal of Clinical Oncology
21. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
    Steve Lu, Julie E. Stein, David L. Rimm, Daphne W. Wang, Michael A. Bell, Douglas Buckner Johnson, Jeffrey Alan Sosman, Kurt Alex Schalper, Robert A. Anders, Hao Wang et al. · 2019 · JAMA Oncology
22. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
    Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan, Lan, Zhengdao, Li, Jun et al. · 2019 · Cancer Cell
23. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
    Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai, Tingbo Liang · 2021 · Signal Transduction and Targeted Therapy
24. Pathways of Colorectal Carcinogenesis
    Nguyen, Long H., Goel, Ajay, Chung, Daniel C. · 2020 · Gastroenterology
25. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
    Bardhan, Kankana, Anagnostou, Theodora, Boussiotis, Vassiliki A. · 2016 · Frontiers in Immunology
26. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Florent Petitprez, Maxime Meylan, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman · 2020 · Frontiers in Immunology
27. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
    Harding, James J., Nandakumar, Subhiksha, Armenia, Joshua, Khalil, Danny N., Albano, Melanie, Ly, Michele, Shia, Jinru, Hechtman, Jaclyn F., Kundra, Ritika, El Dika, Imane et al. · 2019 · Clinical Cancer Research
28. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Harold J. Burstein, Lada Krilov, Jeanny B. Aragon‐Ching, Nancy Noel Baxter, Elena Gabriela Chiorean, Warren Allen Chow, John Frederick De Groot, Steven Michael Devine, Steven G. DuBois, Wafik S. El‐Deiry et al. · 2017 · Journal of Clinical Oncology
29. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
30. Circulating tumor DNA and liquid biopsy in oncology
    Cescon, David W., Bratman, Scott V., Chan, Steven M., Siu, Lillian L. · 2020 · Nature Cancer
31. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
    Yi-Mi Wu, Marcin P. Cieslik, Robert J. Lonigro, Pankaj Vats, Melissa Andrea Reimers, Xuhong Cao, Ning Yu, Lisha Wang, Lakshmi Priya Kunju, Navonil De Sarkar et al. · 2018 · Cell
32. RNA sequencing: new technologies and applications in cancer research
    Mingye Hong, Shuang Tao, Ling Zhang, Li‐Ting Diao, Xuanmei Huang, Shaohui Huang, Shu‐Juan Xie, Zhen‐Dong Xiao, Hua Zhang · 2020 · Journal of Hematology & Oncology
33. Molecular and histological correlations in liver cancer
    Julien Caldéraro, Marianne Ziol, Valérie Paradis, Jessica Zucman‐Rossi · 2019 · Journal of Hepatology
34. Applications of single-cell sequencing in cancer research: progress and perspectives
    Yalan Lei, Rong Tang, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu, Si Shi · 2021 · Journal of Hematology & Oncology
35. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
    Corcoran, Ryan B., André, Thierry, Atreya, Chloe E., Schellens, Jan H.M., Yoshino, Takayuki, Bendell, Johanna C., Hollebecque, Antoine, McRee, Autumn J., Siena, Salvatore, Middleton, Gary et al. · 2018 · Cancer Discovery
36. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
    Cottrell, T.R., Thompson, E.D., Forde, P.M., Stein, J.E., Duffield, A.S., Anagnostou, V., Rekhtman, N., Anders, R.A., Cuda, J.D., Illei, P.B. et al. · 2018 · Annals of Oncology
37. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy
    Becht, Etienne, de Reyniès, Aurélien, Giraldo, Nicolas A., Pilati, Camilla, Buttard, Bénédicte, Lacroix, Laetitia, Selves, Janick, Sautès-Fridman, Catherine, Laurent-Puig, Pierre, Fridman, Wolf Herman · 2016 · Clinical Cancer Research
38. Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis
    Xia, Tianli, Konno, Hiroyasu, Ahn, Jeonghyun, Barber, Glen N. · 2016 · Cell Reports
39. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
    Max D. Wellenstein, Karin E. de Visser · 2018 · Immunity
40. Current recommendations and recent progress in endometrial cancer
    Rebecca Ann Brooks, Gini F. Fleming, Ricardo R. Lastra, Nita Karnik Lee, John William Moroney, Christina H. Son, Ken Tatebe, Jennifer Taylor Veneris · 2019 · CA A Cancer Journal for Clinicians
41. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
    Nadeem R. Abu‐Rustum, Catheryn M. Yashar, Rebecca Christian Arend, Emma Longley Barber, Kristin A. Bradley, Rebecca Ann Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu et al. · 2023 · Journal of the National Comprehensive Cancer Network
42. Cancer Neoantigens
    Ton N. Schumacher, Wouter Scheper, Pia Kvistborg · 2018 · Annual Review of Immunology
43. Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial
    Eng, Cathy, Kim, Tae Won, Bendell, Johanna, Argilés, Guillem, Tebbutt, Niall C, Di Bartolomeo, Maria, Falcone, Alfredo, Fakih, Marwan, Kozloff, Mark, Segal, Neil H et al. · 2019 · The Lancet Oncology
44. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    Jin, Yueping, Dong, Hui, Xia, Liliang, Yang, Yi, Zhu, Yongqiang, Shen, Yan, Zheng, Huajun, Yao, Chengcheng, Wang, Ying, Lu, Shun · 2019 · Journal of Thoracic Oncology
45. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T.W., Ismail, F., Tan, I.B., Yeh, K.-H. et al. · 2018 · Annals of Oncology
46. Gut Microbiota, Inflammation, and Colorectal Cancer
    Caitlin A. Brennan, Wendy S. Garrett · 2016 · Annual Review of Microbiology
47. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
    Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., Carpentier, A.F. · 2017 · European Journal of Cancer
48. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
    Wouter Scheper, Sander Kelderman, Lorenzo F. Fanchi, Carsten Linnemann, Gavin M. Bendle, Marije A. J. de Rooij, Christian Hirt, Riccardo Mezzadra, Maarten Slagter, Krijn Kristian Dijkstra et al. · 2018 · Nature Medicine
49. Immunological landscape and immunotherapy of hepatocellular carcinoma
    Jesús Prìeto, Ignacio Melero, Bruno Sangro · 2015 · Nature Reviews Gastroenterology & Hepatology
50. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
    Shen, Jianfeng, Ju, Zhenlin, Zhao, Wei, Wang, Lulu, Peng, Yang, Ge, Zhongqi, Nagel, Zachary D., Zou, Jun, Wang, Chen, Kapoor, Prabodh et al. · 2018 · Nature Medicine
51. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
    Leisha A. Emens, Paolo A. Ascierto, Phillip Kevin Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco Maria Marincola · 2017 · European Journal of Cancer
52. The foundations of immune checkpoint blockade and the ipilimumab approval decennial
    Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg · 2021 · Nature Reviews Drug Discovery
53. Next generation of immune checkpoint inhibitors and beyond
    Julian Andres Marin-Acevedo, ErinMarie O. Kimbrough, Yanyan Lou · 2021 · Journal of Hematology & Oncology
54. DNA mismatch repair in cancer
    Marina Baretti, Dung Thi Le · 2018 · Pharmacology & Therapeutics
55. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Kimberley M. Heinhuis, Willeke Ros, Marleen Kok, Neeltje Steeghs, Jos H. Beijnen, Jan H.M. Schellens · 2019 · Annals of Oncology
56. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    Mark M. Yarchoan, Lee A. Albacker, Alexander C. Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena Vithayathil, Neeha Zaidi, Nilofer Saba Azad, Daniel A. Laheru, Garrett Michael Frampton et al. · 2019 · JCI Insight
57. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
    Baran, Burcin, Mert Ozupek, Nazli, Yerli Tetik, Nihal, Acar, Emine, Bekcioglu, Omer, Baskin, Yasemin · 2018 · Gastroenterology Research
58. Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
    Rajarsi Mandal, Robert M. Samstein, Ken-Wing Lee, Jonathan J. Havel, Hao Wang, Chirag Krishna, Erich Y. Sabio, Vladimir Makarov, Fengshen Kuo, Pedro Blecua et al. · 2019 · Science
59. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
    Michael Jon Pishvaian, Edik Matthew Blais, Jonathan Robert Brody, Emily E. Lyons, Patricia DeArbeloa, Andrew Eugene Hendifar, Sam Mikhail, Vincent M. Chung, Vaibhav Sahai, Davendra P. S. Sohal et al. · 2020 · The Lancet Oncology
60. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M., Kania, Brooke E., Moran, Meredith M., Cipolla, Catharine K., Bluth, Mark J., Chaim, Joshua, Al-Ahmadie, Hikmat et al. · 2018 · Journal of Clinical Oncology
61. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
    Abida, Wassim, Armenia, Joshua, Gopalan, Anuradha, Brennan, Ryan, Walsh, Michael, Barron, David, Danila, Daniel, Rathkopf, Dana, Morris, Michael, Slovin, Susan et al. · 2017 · JCO Precision Oncology
62. Clinical management of metastatic colorectal cancer in the era of precision medicine
    Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep M. Tabernero, Andrès M.R. Cervantes · 2022 · CA A Cancer Journal for Clinicians
63. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Loi, Sherene, Dushyanthen, Sathana, Beavis, Paul A., Salgado, Roberto, Denkert, Carsten, Savas, Peter, Combs, Susan, Rimm, David L., Giltnane, Jennifer M., Estrada, Monica V. et al. · 2016 · Clinical Cancer Research
64. Genetic Mechanisms of Immune Evasion in Colorectal Cancer
    Grasso, Catherine S., Giannakis, Marios, Wells, Daniel K., Hamada, Tsuyoshi, Mu, Xinmeng Jasmine, Quist, Michael, Nowak, Jonathan A., Nishihara, Reiko, Qian, Zhi Rong, Inamura, Kentaro et al. · 2018 · Cancer Discovery
65. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Luoyan Ai, Antao Xu, Jie Xu · 2020 · Advances in experimental medicine and biology
66. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
    Matthew B.B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Brian A Allen, Hajime Uno, Jason L. Hornick, Chinedu I. Ukaegbu, Lauren K. Brais, Philip G. McNamara, Robert James Mayer et al. · 2017 · Journal of Clinical Oncology
67. Application of PD-1 Blockade in Cancer Immunotherapy
    Xiaomo Wu, Zhongkai Gu, Chen Yang, Borui Chen, Wei Chen, Liqiang Weng, Xiaolong Liu · 2019 · Computational and Structural Biotechnology Journal
68. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
    Andrew Xiuxuan Zhu, Teresa Mercade Macarulla, Milind M. Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John A. Bridgewater et al. · 2021 · JAMA Oncology
69. Optimizing oncolytic virotherapy in cancer treatment
    Kevin Joseph Harrington, Daniel J. Freeman, Elizabeth J. Kelly, James A. Harper, Jean‐Charles Soria · 2019 · Nature Reviews Drug Discovery
70. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
    Kyohei Nakamura, Mark John Smyth · 2019 · Cellular and Molecular Immunology
71. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    Patrick Alexander Ott, Elena Élez, Sandrine Hiret, Dong‐Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M. Mehnert · 2017 · Journal of Clinical Oncology
72. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
    Emilie Picard, Chris P. Verschoor, W Kitonyi Grace, Graham Pawelec · 2020 · Frontiers in Immunology
73. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
    David M. O’Malley, Giovanni Mendonca Bariani, Philippe Alexandre Cassier, Aurélien Marabelle, Aaron Richard Hansen, A. De Jesus Acosta, Wilson H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin et al. · 2022 · Journal of Clinical Oncology
74. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
75. Roles of regulatory T cells in cancer immunity
    Yoshiko Takeuchi, Hiroyoshi Nishikawa · 2016 · International Immunology
76. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
    Diana M. Merino, Lisa M. McShane, David A. Fabrizio, Vincent Anthony Funari, Shu‐Jen Chen, James Robert White, Paul Wenz, Jonathan F. Baden, J. Carl Barrett, Ruchi Chaudhary et al. · 2020 · Journal for ImmunoTherapy of Cancer
77. Microsatellite instability: a review of what the oncologist should know
    Li, Kai, Luo, Haiqing, Huang, Lianfang, Luo, Hui, Zhu, Xiao · 2020 · Cancer Cell International
78. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    Patrick Alexander Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Elena Élez, Michael Jon Pishvaian, Hope S. Rugo, Igor J. Puzanov, Janice M. Mehnert, Kyaw Lwin Aung, Juanita Suzanne Lopez et al. · 2017 · Journal of Clinical Oncology
79. Pembrolizumab (Keytruda)
    Gin Wai Kwok, Thomas C. C. Yau, Joanne Wing Yan Chiu, Eric Tse, Yok‐Lam Kwong · 2016 · Human Vaccines & Immunotherapeutics
80. Comprehensive analysis of the clinical immuno-oncology landscape
    Tang, J., Shalabi, A., Hubbard-Lucey, V.M. · 2018 · Annals of Oncology
81. 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
    Blondy, Sabrina, David, Valentin, Verdier, Mireille, Mathonnet, Muriel, Perraud, Aurélie, Christou, Niki · 2020 · Cancer Science
82. Implementing Genome-Driven Oncology
    David Michael Hyman, Barry S. Taylor, Jose M Baselga · 2017 · Cell
83. Rational combinations of targeted cancer therapies: background, advances and challenges
    Jin, Haojie, Wang, Liqin, Bernards, René · 2023 · Nature Reviews Drug Discovery
84. Targeting the gut and tumor microbiota in cancer
    Park, Elizabeth M., Chelvanambi, Manoj, Bhutiani, Neal, Kroemer, Guido, Zitvogel, Laurence, Wargo, Jennifer A. · 2022 · Nature Medicine
85. Therapeutic targeting of the hypoxic tumour microenvironment
    Dean C. Singleton, Andrew Macann, William Robert Wilson · 2021 · Nature Reviews Clinical Oncology
86. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark Magdi Awad, Patrick Alexander Ott, Raphael Brandão Moreira, Fabio A.B. Schutz, Joaquim Bellmunt B, Guru Sonpavde, Frank Stephen Hodi et al. · 2017 · Cancer Immunology Research
87. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
    Aaron J. Grossberg, Linda Chi Hang Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone et al. · 2020 · CA A Cancer Journal for Clinicians
88. Inflammatory networks underlying colorectal cancer
    Audrey Lasry, Adar Zinger, Yinon Ben‐Neriah · 2016 · Nature Immunology
89. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies
    Sarina Anne Piha-Paul, Do‐Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan M. Nagrial, Robin Kate Kelley, Willeke Ros, Antoîne Italiano, Kazuhiko Nakagawa et al. · 2020 · International Journal of Cancer
90. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
    Carethers, John M., Jung, Barbara H. · 2015 · Gastroenterology
91. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
    Qingzhu Jia, Wei Wu, Yuqi Wang, Peter B. Alexander, Chengdu Sun, Zhihua Gong, Jia-Nan Cheng, Huaibo Sun, Yanfang Guan, Xuefeng Xia et al. · 2018 · Nature Communications
92. PD-L1 Expression in Lung Cancer
    Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
93. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Johnson, Douglas B., Frampton, Garrett M., Rioth, Matthew J., Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C., Fabrizio, David, Chalmers, Zachary R., Greenbowe, Joel et al. · 2016 · Cancer Immunology Research
94. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
    Julien Caldéraro, Florent Petitprez, Étienne Becht, Alexis Laurent, Théo Z. Hirsch, Benoı̂t Rousseau, Alain Luciani, Giuliana Amaddeo, Jonathan Derman, Cécile Charpy et al. · 2018 · Journal of Hepatology
95. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
    Elizabeth D. Thompson, MARIANNA L. ZAHURAK, Adrian Gerard Murphy, Toby C. Cornish, Nathan S. Cuka, Eihab Abdelfatah, Stephen C. Yang, Mark D. Duncan, Nita Ahuja, Janis Marie Taube et al. · 2016 · Gut
96. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky, Rasco, Drew, Vogelzang, Nicholas J, Brose, Marcia S, Cohn, Allen L, Mier, James, Di Simone, Christopher, Hyman, David M, Stepan, Daniel E, Dutcus, Corina E et al. · 2019 · The Lancet Oncology
97. Immune Checkpoint Inhibitors: Basics and Challenges
    Bin Li, Ho Lam Chan, Pingping Chen · 2017 · Current Medicinal Chemistry
98. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
    Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F. et al. · 2022 · Annals of Oncology
99. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
    Daniel P. Hollern, Nuo Xu, Aatish Thennavan, Cherise Ryan Glodowski, Susana García‐Recio, Kevin Raynard Mott, Xiaping He, Joseph P. Garay, Kelly Carey-Ewend, David L. Marron et al. · 2019 · Cell
100. Immunotherapy and Prevention of Pancreatic Cancer
     Alexander H. Morrison, Katelyn T. Byrne, Robert H. Vonderheide · 2018 · Trends in cancer